Methamphetamine
- Atc Codes:N06BA03
- CAS Codes:51-57-0#537-46-2
- PHARMGKB ID:51-57-0#537-46-2
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
North America
USA: Desoxyn.
Asia
Japan: Philopon.
Drug combinations
Chemistry
Methamphetamine Hydrochloride: C~10~H~15~N HCl. Mw: 185.69. (1) Benzeneethanamine, N,α-dimethyl-, hydrochloride, (S)-; (2)(+)-(S)-N,α-Dimethylphenethylamine hydrochloride. CAS-51-57-0; CAS-537-46-2 (methamphetamine).
Pharmacologic Category
Anorexigenic Agents and Respiratory and Cerebral Stimulants; Amphetamines. (ATC-Code: N06BA03).
Mechanism of action
A sympathomimetic amine related to ephedrine and amphetamine with CNS-stimulant activity. Peripheral actions include elevation of systolic and diastolic blood pressure and weak bronchodilator and respiratory stimulant action.
Therapeutic use
Treatment of attention-deficit hyperactivity disorder. Exogenous obesity (short-term adjunct).
Pregnancy and lactiation implications
Teratogenic and embryocidal effects observed in animal studies. Infants may deliver prematurely and suffer withdrawal symptoms. There are no adequate, well-controlled studies in pregnant women. Contraindicated during lactation.
Unlabeled use
Narcolepsy.
Contraindications
Hypersensitivity to methamphetamine, any component of the formulation, or idiosyncrasy to amphetamines or other sympathomimetic amines. Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate-to-severe hypertension, hyperthyroidism, glaucoma, agitated states. History of drug abuse. Use during or within 14 days following MAOI therapy. Stimulant medications contraindicated for use in children with attention-deficit hyperactivity disorders and concomitant Tourette’s syndrome or tics.
Warnings and precautions
Associated with serious cardiovascular events including sudden death in pre-existing structural cardiac abnormalities or other serious heart problems. Amphetamines may impair ability to engage in potentially hazardous activities. Difficulty in accommodation and blurred vision reported with use of stimulants. Use with caution in diabetes mellitus. Potential for drug dependency. Use with caution in hypertension and other cardiovascular conditions that might be exacerbated by increases in blood pressure or heart rate. Use contraindicated in moderate to severe hypertension. Use with caution in pre-existing psychosis or bipolar disorder (may induce mixed/manic episode), in history of seizure disorder, and in Tourette’s syndrome (stimulants might unmask tics). Use of stimulants associated with suppression of growth in children. Abrupt discontinuation following high doses or for prolonged periods may result in symptoms for withdrawal.